Show simple item record

dc.contributor.authorMessina, C
dc.contributor.authorFerreri, A
dc.contributor.authorGovi, S
dc.contributor.authorBruno Ventre, M
dc.contributor.authorGracia Medina, E
dc.contributor.authorPorter, D
dc.contributor.authorRadford, John A
dc.contributor.authorHeo, D
dc.contributor.authorPark, H
dc.contributor.authorPro, B
dc.contributor.authorJayamohan, J
dc.contributor.authorVisco, C
dc.contributor.authorScarfò, L
dc.contributor.authorZucca, E
dc.contributor.authorGospodarowicz, M
dc.contributor.authorChristie, D
dc.date.accessioned2014-07-14T15:08:43Z
dc.date.available2014-07-14T15:08:43Z
dc.date.issued2014-03
dc.identifier.citationClinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). 2014, 164 (6):834-40 Br J Haematolen
dc.identifier.issn1365-2141
dc.identifier.pmid24383942
dc.identifier.doi10.1111/bjh.12714
dc.identifier.urihttp://hdl.handle.net/10541/322893
dc.description.abstract'Multifocal bone lymphoma' or 'polyostotic lymphoma' is a neoplasm with exclusive multifocal involvement of the skeleton, without affecting lymph nodes or other soft tissues. Knowledge on this uncommon condition is limited because the related literature is sparse and fragmentary. We reviewed cases of multifocal bone diffuse large B-cell lymphoma (MB-DLBCL) registered in a clinico-pathological database of the International Extranodal Lymphoma Study Group that includes 499 cases of bone lymphoma. Clinical features, management and prognosis of 37 MB-DLBCL patients and 63 'controls' (stage-IV DLBCL and skeletal involvement) were analysed. Presentation and treatment of MB-DLBCL and controls were identical. At a median follow-up of 52 months (10-189), MB-DLBCL patients exhibited a significantly better response rate (92% vs. 65%; P = 0·002), progression-free survival (5-year: 56 ± 9% vs. 34 ± 6%; P = 0·003) and overall survival (5-year: 74 ± 8% vs. 36 ± 7%; P = 0·002). Among MB-DLBCL patients, the use of post-chemo radiotherapy was associated with better overall survival (5-year: 83 ± 12% vs. 55 ± 16%; P = 0·003). Two MB-DLBCL patients (5·4%) with spine and skull involvement experienced central nervous system (CNS) relapse. Thus, MB-DLBCL patients exhibit a significantly better prognosis compared to patients with advanced-stage DLBCL, and should be treated with conventional anthracycline-based chemotherapy, keeping intensified treatment for relapsing cases, considering involved-field radiotherapy, and CNS prophylaxis in high-risk patients.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of haematologyen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBone Neoplasms
dc.subject.meshCase-Control Studies
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLymphoma, Large B-Cell, Diffuse
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titleClinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).en
dc.typeArticleen
dc.contributor.departmentUnit of Lymphoid Malignancies, Department of Onco-Haematology, San Raffaele Scientific Institute, Milan, Italy.en
dc.identifier.journalBritish Journal of Haematologyen
dc.description.collectionLymphoma Research Teamen
html.description.abstract'Multifocal bone lymphoma' or 'polyostotic lymphoma' is a neoplasm with exclusive multifocal involvement of the skeleton, without affecting lymph nodes or other soft tissues. Knowledge on this uncommon condition is limited because the related literature is sparse and fragmentary. We reviewed cases of multifocal bone diffuse large B-cell lymphoma (MB-DLBCL) registered in a clinico-pathological database of the International Extranodal Lymphoma Study Group that includes 499 cases of bone lymphoma. Clinical features, management and prognosis of 37 MB-DLBCL patients and 63 'controls' (stage-IV DLBCL and skeletal involvement) were analysed. Presentation and treatment of MB-DLBCL and controls were identical. At a median follow-up of 52 months (10-189), MB-DLBCL patients exhibited a significantly better response rate (92% vs. 65%; P = 0·002), progression-free survival (5-year: 56 ± 9% vs. 34 ± 6%; P = 0·003) and overall survival (5-year: 74 ± 8% vs. 36 ± 7%; P = 0·002). Among MB-DLBCL patients, the use of post-chemo radiotherapy was associated with better overall survival (5-year: 83 ± 12% vs. 55 ± 16%; P = 0·003). Two MB-DLBCL patients (5·4%) with spine and skull involvement experienced central nervous system (CNS) relapse. Thus, MB-DLBCL patients exhibit a significantly better prognosis compared to patients with advanced-stage DLBCL, and should be treated with conventional anthracycline-based chemotherapy, keeping intensified treatment for relapsing cases, considering involved-field radiotherapy, and CNS prophylaxis in high-risk patients.


This item appears in the following Collection(s)

Show simple item record